---
company: LifeMD, Inc.
ticker: LFMD
form: 8-K
filed: 2026-08-05
accession: 0001493152-26-036170
source: https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/
---

# LifeMD (LFMD) earnings release, August 5, 2026

LifeMD, Inc. (LFMD) · Form 8-K, Item 2.02 · Filed 2026-08-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/)

Exhibit

99.1

LifeMD

Reports Second Quarter 2026 Results

Conference call begins at 4:30 p.m. Eastern time today

NEW

YORK, August 5, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the second quarter ended June 30, 2026.

Management

Commentary

“Revenue of $47.3 million came in within our guidance range, and while adjusted EBITDA finished below the range we guided to, it improved approximately

21% sequentially. Most importantly, we understand the drivers of the result and have already taken steps to improve performance in the second half. At the same time, the quarter included meaningful progress in reshaping the business around longer-duration members, branded therapies, pharmacy, insurance, and new partnerships. The near-term impact on profitability was greater than we anticipated, but the decisions we made during the quarter are already driving a substantial shift towards what we believe will be higher LTV subscribers,” said Justin Schreiber, Chairman and CEO of LifeMD.

“Our model remains simple: Quality Care. Quality Products. Quality Revenue. We are building around longer patient relationships and a more diversified acquisition model, with increasing contributions over time from pharmaceutical manufacturers, employers, insurers, Medicare, referrals, and cross-care within our existing patient base. Following the pricing change in weight management, the share of new patients selecting multi-month packages increased from approximately 25% year to date before the change to approximately 85% after it. We believe these longer-duration relationships can support better outcomes, stronger retention, higher lifetime value, and more predictable revenue over time.

“This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company that is more diversified. We are also encouraged by the progress we are seeing in Women’s Health, the launch of XYOSTED® with

Halozyme, the continued expansion of our pharmacy, and the development of our pharmaceutical, enterprise, insurance, and Medicare channels.

We expect to return to positive adjusted EBITDA in the second half and to exit 2026 at an annualized revenue run rate of approximately

$250 million with approximately $22 million of annualized adjusted EBITDA. LifeMD has never been better positioned, and the second half of this year will begin to demonstrate what our expanding platform is capable of,” concluded Mr. Schreiber.

“The second quarter reflected the planned step-down in marketing investment we described on our last call, with selling and marketing expense declining $1.8 million sequentially and other general and administrative expenses declining by approximately $2.2 million,” said

Atul Kavthekar, Chief Financial Officer of LifeMD. “Revenue aligned with our expectations in the quarter, and gross margin expanded to approximately 89%, driven by lower shipping and fulfillment costs, improved provider efficiency, and the continued scaling of our in-house pharmacy. Our recurring rebill base now represents approximately 84% of revenue and is the profit engine that funds our growth.

We exited the quarter with $25.1 million in cash and no debt, and we amended our revolving credit facility, further strengthening our financial flexibility. As more patients choose longer-duration subscription plans and marketing spend declines in the second half, we expect cash to build through year-end.”

Second

Quarter 2026 Financial Highlights

All comparisons are with the second quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

Second

Quarter Key Performance Metrics

Positioned for a Strong Second Half

LifeMD enters the second half with improving acquisition trends, a growing recurring patient base, and a broader set of growth channels taking shape. Priorities for the remainder of 2026 include scaling longer-duration weight management memberships, expanding Women’s Health and the XYOSTED® collaboration, increasing pharmacy attachment, and advancing pharmaceutical, insurance, Medicare, employer, and enterprise relationships. Together, these initiatives should reduce reliance on paid media, deepen patient relationships, and support improving operating leverage and financial performance through year-end.

Financial

Guidance

For the third quarter of 2026, the Company expects:

For the full year 2026, the Company expects (revised from previous guidance):

Conference

Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About

LifeMD, Inc.

LifeMD® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, please visit LifeMD.com.

Cautionary

Note Regarding Forward Looking Statements

This... (truncated)es Act of 1933, as amended; Section

21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform

Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,”

“expect,” “anticipate,” “project,” “should,” “plan,” “will,”

“may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor

Contact ir@lifemd.com

Media

Contact press@lifemd.com

Tables to Follow

++++++

LIFEMD,

INC.

## Financial statements

### Income Statement (($ in 000s) — Second Quarter Key Performance Metrics)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Y-o-Y – % Growth |
|---|---:|---:|---:|
| Revenue | 47,281 | 49,019 | -4.0% |
| Gross Profit | 41,997 | 42,180 | 0.0% |
| Gross Margin % | 89.0% | 86 | +280bpts |
| Adjusted EBITDA | -3,530 | 3,886 | -191.0% |
| Active Subscribers | 355,671 | 296,946 | 20.0% |

### Income Statement (Three Months Ended June 30, — (Unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Telehealth revenue, net | 47,281,085 | 49,018,882 | 97,444,041 | 99,906,781 |
| Cost of telehealth revenue | 5,284,323 | 6,838,703 | 11,209,822 | 14,975,164 |
| Gross profit | 41,996,762 | 42,180,179 | 86,234,219 | 84,931,617 |
| Expenses | Selling and marketing expenses | 28,035,947 | 22,151,114 | 57,910,807 | 44,424,036 |
| Expenses | General and administrative expenses | 13,645,809 | 14,439,140 | 28,822,164 | 28,779,294 |
| Expenses | Other operating expenses | 3,040,187 | 2,883,015 | 6,220,133 | 5,272,551 |
| Expenses | Customer service expenses | 2,612,986 | 3,230,735 | 5,752,291 | 6,302,229 |
| Expenses | Development costs | 1,791,434 | 1,823,061 | 3,587,497 | 3,682,110 |
| Expenses | Total expenses | 49,126,363 | 44,527,065 | 102,292,892 | 88,460,220 |
| Expenses | Operating loss from continuing operations | -7,129,601 | -2,346,886 | -16,058,673 | -3,528,603 |
| Expenses | Interest income (expense), net | 45,660 | -660,787 | 102,136 | -1,124,425 |
| Expenses | Loss from continuing operations before income taxes | -7,083,941 | -3,007,673 | -15,956,537 | -4,653,028 |
| Expenses | Net loss from continuing operations | -7,083,941 | -3,007,673 | -15,956,537 | -4,653,028 |
| Expenses | Net income from discontinued operations |  | 1,893,084 |  | 3,886,506 |
| Expenses | Net loss | -7,083,941 | -1,114,589 | -15,956,537 | -766,522 |
| Expenses | Net income attributable to noncontrolling interests of discontinued operations |  | 505,075 |  | 1,036,920 |
| Expenses | Net loss attributable to LifeMD, Inc. | -7,083,941 | -1,619,664 | -15,956,537 | -1,803,442 |
| Expenses | Preferred stock dividends | -776,562 | -776,562 | -1,553,125 | -1,553,125 |
| Expenses | Net loss attributable to LifeMD, Inc. common stockholders | -7,860,503 | -2,396,226 | -17,509,662 | -3,356,567 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Continuing operations | -0.16 | -0.09 | -0.37 | -0.14 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Discontinued operations |  | 0.03 |  | 0.07 |
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Basic loss per share | -0.16 | -0.05 | -0.37 | -0.08 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Continuing operations | -0.16 | -0.09 | -0.37 | -0.14 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Discontinued operations |  | 0.03 |  | 0.07 |
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | Diluted loss per share | -0.16 | -0.05 | -0.37 | -0.08 |
| Weighted average number of common shares outstanding: | Basic | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |
| Weighted average number of common shares outstanding: | Diluted | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 |

### Balance Sheet (June 30, 2026 — (Unaudited))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current Assets | Cash | 25,141,615 | 36,786,318 |
| Current Assets | Accounts receivable | 11,256,158 | 9,305,277 |
| Current Assets | Product deposit | 243,759 | 320,217 |
| Current Assets | Inventory, net | 2,956,144 | 2,773,576 |
| Current Assets | Other current assets | 2,486,803 | 2,646,077 |
| Current Assets | Total Current Assets | 42,084,479 | 51,831,465 |
| Non-current Assets | Equipment, net | 2,035,475 | 2,444,717 |
| Non-current Assets | Right of use assets, net | 4,839,958 | 5,267,857 |
| Non-current Assets | Capitalized software, net | 10,734,486 | 10,604,946 |
| Non-current Assets | Intangible assets, net | 198,500 | 262,334 |
| Non-current Assets | Total Non-current Assets | 17,808,419 | 18,579,854 |
| Non-current Assets | Total Assets | 59,892,898 | 70,411,319 |
| Current Liabilities | Accounts payable | 18,156,912 | 14,149,154 |
| Current Liabilities | Accrued expenses | 16,961,186 | 15,974,016 |
| Current Liabilities | Current operating lease liabilities | 699,511 | 642,422 |
| Current Liabilities | Deferred revenue | 10,791,221 | 10,807,773 |
| Current Liabilities | Total Current Liabilities | 46,608,830 | 41,573,365 |
| Long-term Liabilities | Noncurrent operating lease liabilities | 5,317,613 | 5,681,374 |
| Long-term Liabilities | Total Liabilities | 51,926,443 | 47,254,739 |
| Stockholders’ Equity | Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | 140 | 140 |
| Stockholders’ Equity | Common Stock, $0.01 par value; 100,000,000 shares authorized, 47,923,532 and 46,760,016 shares issued, 47,820,492 and 46,656,976 outstanding as of June 30, 2026 and December 31, 2025, respectively | 479,235 | 467,600 |
| Stockholders’ Equity | Additional paid-in capital | 253,763,518 | 251,455,616 |
| Stockholders’ Equity | Accumulated deficit | -246,112,737 | -228,603,075 |
| Stockholders’ Equity | Treasury stock, 103,040 shares, at cost, as of June 30, 2026 and December 31, 2025 | -163,701 | -163,701 |
| Stockholders’ Equity | Total Stockholders’ Equity | 7,966,455 | 23,156,580 |
| Stockholders’ Equity | Total Liabilities and Stockholders’ Equity | 59,892,898 | 70,411,319 |

### Cash Flow (Three Months Ended June 30, — (Unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net loss | -7,083,941 | -1,114,589 | -15,956,537 | -766,522 |
| CASH FLOWS FROM OPERATING ACTIVITIES | Less: Net income from discontinued operations |  | 1,893,084 |  | 3,886,506 |
